Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 838

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 838
---
 |     | Level 3 |         |     | Total |         |
| Derivative Liability |     | $                 | — |     | $       | — |     | $       | 137,000 |     | $     | 137,000 |
| Total Liabilities    |     | $                 | — |     | $       | — |     | $       | 137,000 |     | $     | 137,000 |

There were no transfers between the Level 1, Level 2 or Level 3 categories during the years ended December 31, 2024 and 2023.

Derivative Liability

The following table presents activity for the Derivative Liability that were measured at fair value using significant unobservable Level 3 inputs during the years ended December 31, 2024 and, 2023:

| Balance as of January 1, 2023                                   |     | DerivativeLiability |          — |   |
|:----------------------------------------------------------------|:----|:--------------------|-----------:|:--|
| Additions (make-whole provision in convertible notes agreement) |     |                     |    137,000 |   |
| Change in fair value                                            |     |                     |          — |   |
| Balance as of December 31, 2023                                 |     | $                   |    137,000 |   |
| Additions (make-whole provision in convertible notes agreement) |     |                     |  2,402,228 |   |
| Change in fair value                                            |     |                     |    313,772 |   |
| Reclassification to additionalpaid-incapital                    |     |                     | (2,853,000 | ) |
| Balance as of December 31, 2024                                 |     | $                   |          — |   |

Note 6 - Merger with Kintara Therapeutics Under the terms of the Merger, immediately prior to the effective time of the Merger, shares of the Company’s preferred stock were converted into shares of Company common stock and all of the Notes issued by the Company were converted into shares of Company common stock pursuant to the terms therein. At the effective time of the Merger, (i) Kintara issued an aggregate of approximately 40,441,605shares of its common stock to Company stockholders, based on an exchange ratio of 0.1789(after giving effect to the Reverse Stock Split) shares of Kintara’s common stock for each